从使用DeepALZNET双通道框架的临床和MRI数据预测阿尔茨海默病
Saddam Bekhet1, Nagwa Saad2, Sara Farag2
1Faculty of Commerce, South Valley University, Qena, 83523, Egypt. saddam.bekhet@svu.edu.eg.
Scientific reports
|December 4, 2025
概括
这项研究介绍了DeepALZNET,这是一种用于使用临床数据或脑MRI扫描预测早期阿尔茨海默病 (AD) 的新型计算框架. DeepALZNET提供了一种实用,可适应的方法,用于及时诊断和干预.
科学领域:
- 神经学 神经学
- 计算神经科学是一种神经科学.
- 医学成像分析 医学成像分析
背景情况:
- 阿尔茨海默病 (AD) 呈现出逐渐的认知衰退,由于微妙的早期症状,诊断往往会延迟.
- 缺乏有效的治疗方法强调了急需早期和准确的诊断工具,以控制疾病的进展.
- 当前的先进方法往往需要大量的数据和计算资源,这限制了实际应用.
研究的目的:
- 介绍DeepALZNET,一个双路径计算框架,用于增强阿尔茨海默病的预测.
- 提供一种实用,可解释和适应的解决方案,用于早期AD诊断,使用临床数据或大脑MRI.
- 开发一个系统,弥合研究基准和现实世界的可部署解决方案之间的差距.
主要方法:
- 一个双路径框架:一个路径用于结构化临床数据 (1D CNN + 随机森林),另一个路径用于非结构化脑MRI扫描 (VGG19转移学习).
- 在公开数据集 (2k 个临床病例,40k 个MRI 图像) 和已建立的基准 (ADNI,OASIS) 上进行实证验证.
- 专注于实际适用性,可解释性和适应性,与资源密集型变压器或基于注意力的方法形成鲜明对比.
主要成果:
- 这两种DeepALZNET途径在预测阿尔茨海默病方面都取得了竞争力的准确性.
- 该框架在不同数据集和基准中表现出强度.
- 该系统使用临床数据或MRI扫描独立有效运行,突出其灵活性.
结论:
- DeepALZNET提供了一个可行的和实用的计算框架,用于早期发现阿尔茨海默病.
- 双通道设计提高了诊断准确性和在临床环境中的适用性.
- 未来的工作可以在DeepALZNET框架内探索多式联接和注意力机制.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
764
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
764


